(ATXS) Astria Therapeutics - Ratings and Ratios
Monoclonal, Antibody, Plasma, Kallikrein, OX40
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 60.2% |
| Value at Risk 5%th | 95.2% |
| Relative Tail Risk | -3.95% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.61 |
| Alpha | 8.49 |
| CAGR/Max DD | 0.08 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.604 |
| Beta | 1.244 |
| Beta Downside | 1.511 |
| Drawdowns 3y | |
|---|---|
| Max DD | 77.53% |
| Mean DD | 41.41% |
| Median DD | 43.29% |
Description: ATXS Astria Therapeutics October 26, 2025
Astria Therapeutics, Inc. (NASDAQ: ATXS) is a Boston-based biopharmaceutical firm focused on developing novel therapeutics for allergic and immunological diseases in the United States. The company, originally incorporated as Catabasis Pharmaceuticals in 2008, rebranded to Astria in September 2021.
The lead asset, **navenibart**, is a monoclonal antibody that inhibits plasma kallikrein. It is currently in a combined Phase 1b/2 trial for hereditary angioedema (HAE), a rare disease with an estimated U.S. market size of roughly $2 billion and growing demand for sub-cut injectable therapies.
A second pipeline candidate, **STAR-0310**, is an OX40 antagonist monoclonal antibody being evaluated for atopic dermatitis (AD). AD represents a $5 billion global market, and OX40-targeted agents have shown promise in early-stage trials for enhancing skin-barrier restoration and reducing pruritus.
As of the latest filing (Q3 2024), Astria reported cash and cash equivalents of approximately $120 million, giving it an estimated 12-month runway at current burn rates. The broader biotech sector continues to benefit from elevated R&D capital inflows-venture funding to U.S. biotech reached a record $45 billion in 2023-while reimbursement pressures remain a key economic driver for specialty biologics.
For a deeper dive into ATXS’s valuation metrics and how they compare to sector peers, you may find the analytics on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-124.0m TTM) > 0 and > 6% of Revenue (6% = 42.4k TTM) |
| FCFTA -0.44 (>2.0%) and ΔFCFTA -18.15pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.44 (>3.0%) and CFO -119.7m > Net Income -124.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 10.78 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (58.0m) change vs 12m ago 2.69% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.22% (prev 0.0%; Δ 0.22pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -4.72 (EBITDA TTM -134.0m / Interest Expense TTM 21.7m) >= 6 (WARN >= 3) |
Altman Z'' -26.92
| (A) 0.85 = (Total Current Assets 253.5m - Total Current Liabilities 23.5m) / Total Assets 271.9m |
| (B) -2.84 = Retained Earnings (Balance) -773.2m / Total Assets 271.9m |
| warn (B) unusual magnitude: -2.84 — check mapping/units |
| (C) -0.32 = EBIT TTM -102.4m / Avg Total Assets 316.8m |
| (D) -20.02 = Book Value of Equity -773.1m / Total Liabilities 38.6m |
| Total Rating: -26.92 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 35.57
| 1. Piotroski 0.0pt |
| 2. FCF Yield -24.26% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.02 |
| 5. Debt/Ebitda 0.68 |
| 6. ROIC - WACC (= -55.40)% |
| 7. RoE -45.01% |
| 8. Rev. Trend 42.01% |
| 9. EPS Trend 55.47% |
What is the price of ATXS shares?
Over the past week, the price has changed by +3.89%, over one month by +5.65%, over three months by +87.27% and over the past year by +27.96%.
Is ATXS a buy, sell or hold?
- Strong Buy: 7
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ATXS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24.6 | 87.9% |
| Analysts Target Price | 24.6 | 87.9% |
| ValueRay Target Price | 13.1 | 0.4% |
ATXS Fundamental Data Overview November 29, 2025
P/S = 1018.7946
P/B = 5.2148
Beta = 0.075
Revenue TTM = 706.0k USD
EBIT TTM = -102.4m USD
EBITDA TTM = -134.0m USD
Long Term Debt = 4.46m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.40m USD (from shortTermDebt, last quarter)
Debt = 4.46m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -91.8m USD (from netDebt column, last quarter)
Enterprise Value = 496.0m USD (719.3m + Debt 4.46m - CCE 227.7m)
Interest Coverage Ratio = -4.72 (Ebit TTM -102.4m / Interest Expense TTM 21.7m)
FCF Yield = -24.26% (FCF TTM -120.3m / Enterprise Value 496.0m)
FCF Margin = -17.0k% (FCF TTM -120.3m / Revenue TTM 706.0k)
Net Margin = -17.6k% (Net Income TTM -124.0m / Revenue TTM 706.0k)
Gross Margin = -9999 % ((Revenue TTM 706.0k - Cost of Revenue TTM 137.2m) / Revenue TTM)
Gross Margin QoQ = -4831 % (prev none%)
Tobins Q-Ratio = 1.82 (Enterprise Value 496.0m / Total Assets 271.9m)
Interest Expense / Debt = 51.69% (Interest Expense 2.31m / Debt 4.46m)
Taxrate = 21.0% (US default 21%)
NOPAT = -80.9m (EBIT -102.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.78 (Total Current Assets 253.5m / Total Current Liabilities 23.5m)
Debt / Equity = 0.02 (Debt 4.46m / totalStockholderEquity, last quarter 233.3m)
Debt / EBITDA = 0.68 (negative EBITDA) (Net Debt -91.8m / EBITDA -134.0m)
Debt / FCF = 0.76 (negative FCF - burning cash) (Net Debt -91.8m / FCF TTM -120.3m)
Total Stockholder Equity = 275.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -45.62% (Net Income -124.0m / Total Assets 271.9m)
RoE = -45.01% (Net Income TTM -124.0m / Total Stockholder Equity 275.6m)
RoCE = -36.55% (EBIT -102.4m / Capital Employed (Equity 275.6m + L.T.Debt 4.46m))
RoIC = -44.86% (negative operating profit) (NOPAT -80.9m / Invested Capital 180.3m)
WACC = 10.53% (E(719.3m)/V(723.7m) * Re(10.60%) + (debt cost/tax rate unavailable))
Discount Rate = 10.60% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 26.02%
Fair Price DCF = unknown (Cash Flow -120.3m)
EPS Correlation: 55.47 | EPS CAGR: 301.0% | SUE: -2.05 | # QB: 0
Revenue Correlation: 42.01 | Revenue CAGR: 89.54% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.59 | Chg30d=+0.015 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=-2.36 | Chg30d=+0.025 | Revisions Net=-1 | Growth EPS=-11.0% | Growth Revenue=-66.0%
Additional Sources for ATXS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle